Aromatase Inhibitors

  • Barrington J.A. Furr

Part of the Milestones in Drug Therapy MDT book series (MDT)

Table of contents

  1. Front Matter
    Pages I-X
  2. Jürgen Geisler, Per Eystein Lønning
    Pages 45-52
  3. Robert J. Paridaens
    Pages 53-64
  4. J. Michael Dixon
    Pages 65-93
  5. Anthony Howell, Alan Wakeling
    Pages 95-118
  6. Evan R. Simpson, Margaret E. Jones, Colin D. Clyne
    Pages 139-155
  7. Back Matter
    Pages 177-182

About this book


Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase).
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.


Brustkrebs Clinical Overview Clinical Pharmacology Drogen Drugs Exemestane Letrazole breast cancer cancer clinical trial enzyme hormone therapy hormones pharmacology tumor

Editors and affiliations

  • Barrington J.A. Furr
    • 1
  1. 1.AstraZenecaGlobal DiscoveryMacclesfield, CheshireUK

Bibliographic information